|
Study | Participants | Intervention (dose) | | Duration of study | Control |
|
Allegra et al., 1981 [38] | Patients with venous insufficiency of the lower limbs | TTFCA (60 mg/day) | 80 | 30 days | placebo |
Marastoni et al., 1982 [39] | Patients with CVI | Centella asiatica extract (tid)* | 17 | 4 weeks | tribenoside |
Pointel et al., 1987 [40] | Patients with venous insufficiency of the lower limbs | TTFCA (60 mg; 120 mg) | 94 | 8 weeks | placebo |
Cesarone et al., 1994 [41] | Patients with chronic venous hypertensive microangiopathy | TTFCA (30 mg bid; 60 mg bid) | 90 | 60 days | placebo |
Cesarone et al., 2001 [42] | Patients with severe venous hypertension, ankle swelling, and lipodermatosclerosis | TTFCA (60 mg bid) | 40 | 8 weeks | placebo |
Cesarone et al., 2001 [43] | Patients with venous hypertension with ankle and foot swelling, oedema, and lipodermatosclerosis, with intact skin | TTFCA (60 mg bid) | 40 | 6 weeks | placebo |
De Sanctis et al., 2001 [44] | Patients with venous hypertension (ambulatory venous pressure > 42 mm Hg) | TTFCA (30 mg tid; 60 mg tid) | 62 | 4 weeks | placebo |
Incandela et al., 2001 [45] | Patients with venous hypertensive microangiopathy | TTFCA (60 mg daily; 120 mg daily) | 99 | 8 weeks | placebo |
|